ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

BARDA expands Basilea’s funding

by Lisa M. Jarvis
June 19, 2017 | APPEARED IN VOLUME 95, ISSUE 25

The Biomedical Advanced Research & Development Authority (BARDA) has agreed to give Basilea Pharmaceutica an additional $54.8 million on an existing contract to support late-stage studies of ceftobiprole. The cephalosporin antibiotic is being explored as a treatment for bloodstream infections caused by Staphylococcusaureus and skin infections. Basilea recently reached an agreement with FDA on the design of Phase III studies, which the company expects to begin within the next three to six months. Basilea could receive a total of $108 million under the BARDA contract.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment